Gilead Sciences Says High Cure Rates Observed With Single Tablet Regimen May Eliminate Interferon And Ribavirin From Hcv Therapy For Genotype 1 Patients
Gilead Sciences (Nasdaq: GILD) today announced topline results
from three Phase 3 clinical trials (ION-1, ION-2 and ION-3) evaluating
the investigational once-daily fixed-dose combination of the nucleotide
analog polymerase inhibitor sofosbuvir (SOF) 400 mg and the NS5A
inhibitor ledipasvir (LDV) 90 mg, with and without ribavirin (RBV), for
the treatment of genotype 1 chronic hepatitis C virus (HCV) infection.
Across the three studies, 1,952 patients with genotype 1 HCV infection
were randomized to receive SOF/LDV with or without RBV for eight, 12 or
24 weeks of therapy. Of these, 1,512 patients were treatment-naïve, 440
were treatment experienced and 224 had compensated cirrhosis.
The intent-to-treat SVR12 rates observed to date in the ION